Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate

Bone

Volumn 49, Issue 1, 2011, Pages 128-132

  Allen, Matthew R ^a   Turek, John J ^a,d   Phipps, Roger J ^c   Burr, David B ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

^c HUSSON UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Bone remodeling; Histomorphometry; Rabbit model

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; DIAPHYSIS; DRUG MEGADOSE; DRUG POTENCY; FEMALE; LOW DRUG DOSE; LUMBAR VERTEBRA; NONHUMAN; OSTEOCLAST; RABBIT; TIBIA; TRABECULAR BONE;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIAPHYSES; ETIDRONIC ACID; FEMALE; FLUORESCENT DYES; RABBITS; SPINE; TIBIA; TIME FACTORS;

EID: 79958725363     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2010.07.011     Document Type: Article

References (21)

1. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
2. Bonnick S., Saag K.G., Kiel D.P., McClung M., Hochberg M., Burnett S.M., Sebba A., Kagan R., Chen E., Thompson D.E., de Papp A.E. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006, 91:2631-2637.
3. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., Kagan R., Chen E., Petruschke R.A., Thompson D.E., de Papp A.E. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
4. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., Kavanagh K.L., Triffitt J.T., Lundy M.W., Phipps R.J., Barnett B.L., Coxon F.P., Rogers M.J., Watts N.B., Ebetino F.H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
5. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G., Oppermann U., Kavanagh K.L., Watts N.B. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51:2187-2195.
6. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
7. Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 2008, 42:1014-1020.
8. Gilsanz V., Roe T.F., Gibbens D.T., Schulz E.E., Carlson M.E., Gonzalez O., Boechat M.I. Effect of sex steroids on peak bone density of growing rabbits. Am J Physiol 1988, 255:E416-E421.
9. Feher A., Koivunemi A., Koivunemi M., Fuchs R.K., Burr D.B., Phipps R.J., Reinwald S., Allen M.R. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 2010, 46:203-207.
10. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover following discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23:1689-1697.
11. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., Nevitt M.C., Suryawanshi S., Cummings S.R. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
12. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., Felsenberg D., Songcharoen S., Rizzoli R., Di Munno O., Horlait S., Valent D., Watts N.B. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004, 20:433-439.
13. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., Barton I., Boonen S. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74:129-135.
14. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18:25-34.
15. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
16. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
17. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G. Ebetino FH 2005, Differences in interactions with hydroxyapatite. Bone, Novel insights into actions of bisphosphonates on bone.
18. Allen M.R., Follet H., Khurana M., Sato M., Burr D.B. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcified Tissue International 2006, 79:255-261.
19. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcified Tissue International 2008, 82:354-360.
20. Mashiba T., Burr D.B., Turner C.H., Sato M., Cain R.L., Hock J.M. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538-547.
21. Iwata K., Li J., Follet H., Phipps R.J., Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independent of resorption in rat femur and tibia. Bone 2006, 39:1053-1058.